Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14712897 | 0.85 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12424732 | 0.80 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL10965124 | 0.78 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4474372 | 0.77 | MAPK14 (0.93) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL828140 | 0.76 | MAPK14 (0.93) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4467002 | 0.75 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13712661 | 0.74 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL828375 | 0.73 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14712903 | 0.72 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4464730 | 0.71 | MAPK14 (0.94) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | MAPK14 53/4885MAPK13 71/4885MAPK12 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.